Payment overview · 2025
General Payments
$277.60
10 reported records · 6 companies
Healthcare provider profile · identity verified
Adam R Knutson, DO
Allopathic & Osteopathic Physicians|Internal Medicine · CORVALLIS, OR · NPI 1912352402
Verified facts
What the public records show
CMS Open Payments records show Adam R Knutson, DO received $277.60 in general payments during 2025 across 10 reported records.
SANOFI PASTEUR INC. accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $114.32 | 41.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $53.47 | 19.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.73 | 17.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $30.24 | 10.9% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.06 | 8.0% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $8.78 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $277.60 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $114.32 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $53.47 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $24.27 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $8.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
113 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 117 |
| Losartan Potassium | Losartan Potassium | 317 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 72 |
| Omeprazole | Omeprazole | 223 | 67 |
| Lisinopril | Lisinopril | 222 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 55 |
| Gabapentin | Gabapentin | 174 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 142 | 44 |
| Furosemide | Furosemide | 128 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 38 |
| Trazodone Hcl | Trazodone Hcl | 115 | 34 |
| Metformin Hcl | Metformin Hcl | 114 | 37 |
| Eliquis | Apixaban | 113 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 27 |
| Pantoprazole Sodium | Pantoprazole Sodium | 110 | 32 |
| Jardiance | Empagliflozin | 104 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 31 |
| Carvedilol | Carvedilol | 93 | 30 |
| Metformin Hcl Er | Metformin Hcl | 90 | 27 |
| Allopurinol | Allopurinol | 82 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 34 |
| Ozempic | Semaglutide | 80 | 17 |
| Tramadol Hcl | Tramadol Hcl | 80 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 25 |
| Mirtazapine | Mirtazapine | 67 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 66 | 24 |
| Spironolactone | Spironolactone | 65 | 21 |
| Clonazepam | Clonazepam | 57 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 17 |
| Pregabalin | Pregabalin | 56 | 13 |
| Celecoxib | Celecoxib | 54 | 18 |
| Alendronate Sodium | Alendronate Sodium | 51 | 17 |
| Famotidine | Famotidine | 50 | 15 |
| Simvastatin | Simvastatin | 50 | 16 |
| Warfarin Sodium | Warfarin Sodium | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 45 | 14 |
| Potassium Chloride | Potassium Chloride | 45 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 42 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 12 |
| Meloxicam | Meloxicam | 40 | 15 |
| Propranolol Hcl | Propranolol Hcl | 40 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Torsemide | Torsemide | 36 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 17 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | 13 |
| Nystatin | Nystatin | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Finasteride | Finasteride | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Prednisone | Prednisone | 13 | 11 |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $277.60 · 10 records | SANOFI PASTEUR INC. | ABRYSVO, BEYFORTUS, COMIRNATY, GVOKE HYPOPEN, MAVYRET, NEXPLANON, NURTEC ODT, Ozempic, PREVNAR 20, UBRELVY, ZAVZPRET | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error